Patents by Inventor Tinnakorn Chaiworapongsa

Tinnakorn Chaiworapongsa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11906528
    Abstract: Kits and methods to distinguish between false and true labor are provided. The kits and methods can utilize differences in abundance and/or differences in the rate of change in abundance of B7-H2, SORC2, TF, C1-Esterase Inhibitor, Ran, IMDH1 and/or PGAM1, as markers of true labor.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: February 20, 2024
    Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human Services
    Inventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Publication number: 20240027470
    Abstract: Biomarkers tests which can be used to predict a positive or negative risk of preeclampsia are described. More specifically, a panel of biomarkers including MMP-7 and gpIIbIIIa, described. The test is useful to predict preeclampsia when a biological sample is obtained between the 16th and 22nd week of pregnancy. Prediction later in pregnancy can be achieved by a combination of Siglec-6, Activin A, ALCAM, and/or FCN2.
    Type: Application
    Filed: October 6, 2023
    Publication date: January 25, 2024
    Applicants: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human Services
    Inventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Publication number: 20230341414
    Abstract: Provided are systems and methods for assessing the presence or risk of obstetrical complications, particularly those related to an angiogenic and anti-angiogenic imbalance. Also provided are methods of treating an angiogenic and anti-angiogenic imbalance with water-soluble statins, such as pravastatin.
    Type: Application
    Filed: May 10, 2023
    Publication date: October 26, 2023
    Applicants: Wayne State University, The United States of America as Represented by the Secretary., Dept. of Health and Human Services
    Inventors: Tinnakorn Chaiworapongsa, Roberto Romero, Sonia S. Hassan
  • Patent number: 11782065
    Abstract: Biomarkers tests which can be used to predict a positive or negative risk of preeclampsia are described. More specifically, a panel of biomarkers including MMP-7 and gpIIbIIIa, described. The test is useful to predict preeclampsia when a biological sample is obtained between the 16th and 22nd week of pregnancy. Prediction later in pregnancy can be achieved by a combination of Siglec-6, Activin A, ALCAM, and/or FCN2.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: October 10, 2023
    Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human Services
    Inventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Patent number: 11686735
    Abstract: Provided are systems and methods for assessing the presence or risk of obstetrical complications, particularly those related to an angiogenic and anti-angiogenic imbalance. Also provided are methods of treating an angiogenic and anti-angiogenic imbalance with water-soluble statins, such as pravastatin.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: June 27, 2023
    Assignees: WAYNE STATE UNIVERSITY, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Tinnakorn Chaiworapongsa, Roberto Romero, Sonia S. Hassan
  • Publication number: 20220113316
    Abstract: Biomarkers tests which can be used to predict a positive or negative risk of preeclampsia are described. More specifically, a panel of biomarkers including MMP-7 and gpIIbIIIa, described. The test is useful to predict preeclampsia when a biological sample is obtained between the 16th and 22nd week of pregnancy. Prediction later in pregnancy can be achieved by a combination of Siglec-6, Activin A, ALCAM, and/or FCN2.
    Type: Application
    Filed: December 21, 2021
    Publication date: April 14, 2022
    Applicants: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human Services
    Inventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Publication number: 20220065867
    Abstract: Kits and methods to distinguish between false and true labor are provided. The kits and methods can utilize differences in abundance and/or differences in the rate of change in abundance of B7-H2, SORC2, TF, C1-Esterase Inhibitor, Ran, IMDH1 and/or PGAM1, as markers of true labor.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 3, 2022
    Applicants: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health & Human Service
    Inventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Patent number: 11243213
    Abstract: Biomarkers tests which can be used to predict a positive or negative risk of preeclampsia are described. More specifically, a panel of biomarkers including MMP-7 and gpIIbIIIa, described. The test is useful to predict preeclampsia when a biological sample is obtained between the 16th and 22nd week of pregnancy. Prediction later in pregnancy can be achieved by a combination of Siglec-6, Activin A, ALCAM, and/or FCN2.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: February 8, 2022
    Assignees: Wayne State University, The United States of America as Represented by the Secretary, Department of Health and Human Services
    Inventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Patent number: 11204354
    Abstract: Kits and methods to distinguish between false and true labor are provided. The kits and methods can utilize differences in abundance and/or differences in the rate of change in abundance of B7-H2, SORC2, TF, C1-Esterase Inhibitor, Ran, IMD-H1 and/or PGAM1, as markers of true labor.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: December 21, 2021
    Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Dept. of Health and Human Services
    Inventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Patent number: 10802030
    Abstract: Provided are systems and methods to identify subjects at risk for preterm labor and/or preterm birth. The systems and methods utilize biomarkers. Also provided are systems and methods for decreasing the risk of preterm labor by administering a treatment following a positive risk identification.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: October 13, 2020
    Assignees: Wayne State University, The United States of America as Represented by the Secretary, Department of Health and Human Service
    Inventors: Adi L. Tarca, Offer Erez, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Publication number: 20190285643
    Abstract: Provided are systems and methods for assessing the presence or risk of obstetrical complications, particularly those related to an angiogenic and anti-angiogenic imbalance. Also provided are methods of treating an angiogenic and anti-angiogenic imbalance with water-soluble statins, such as pravastatin.
    Type: Application
    Filed: April 17, 2019
    Publication date: September 19, 2019
    Applicants: Wayne State University, The United States of America as Represented by the Secretary, Department of Health and Human Service
    Inventors: Tinnakorn Chaiworapongsa, Roberto Romero, Sonia S. Hassan
  • Patent number: 10281475
    Abstract: Provided are systems and methods for assessing the presence or risk of obstetrical complications, particularly those related to an angiogenic and anti-angiogenic imbalance. Also provided are methods of treating an angiogenic and anti-angiogenic imbalance with water-soluble statins, such as pravastatin.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: May 7, 2019
    Assignees: Wayne State University, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Publication number: 20180328937
    Abstract: Biomarkers tests which can be used to predict a positive or negative risk of preeclampsia are described. More specifically, a panel of biomarkers including MMP-7 and gpIIbIIIa, described. The test is useful to predict preeclampsia when a biological sample is obtained between the 16th and 22nd week of pregnancy. Prediction later in pregnancy can be achieved by a combination of Siglec-6, Activin A, ALCAM, and/or FCN2.
    Type: Application
    Filed: November 7, 2016
    Publication date: November 15, 2018
    Applicants: WAYNE STATE UNIVERSITY, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE
    Inventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Publication number: 20180321250
    Abstract: Kits and methods to distinguish between false and true labor are provided. The kits and methods can utilize differences in abundance and/or differences in the rate of change in abundance of B7-H2, SORC2, TF, C1-Esterase Inhibitor, Ran, IMD-H1 and/or PGAM1, as markers of true labor.
    Type: Application
    Filed: November 7, 2016
    Publication date: November 8, 2018
    Applicants: WAYNE STATE UNIVERSITY, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN
    Inventors: Adi L. Tarca, Piya Chaemsaithong, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Publication number: 20180306803
    Abstract: Provided are systems and methods to identify subjects at risk for preterm labor and/or preterm birth. The systems and methods utilize biomarkers. Also provided are systems and methods for decreasing the risk of preterm labor by administering a treatment following a positive risk identification.
    Type: Application
    Filed: April 20, 2018
    Publication date: October 25, 2018
    Inventors: Adi L. Tarca, Offer Erez, Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero
  • Publication number: 20170242021
    Abstract: Provided are systems and methods for assessing the presence or risk of obstetrical complications, particularly those related to an angiogenic and anti-angiogenic imbalance. Also provided are methods of treating an angiogenic and anti-angiogenic imbalance with water-soluble statins, such as pravastatin.
    Type: Application
    Filed: March 27, 2015
    Publication date: August 24, 2017
    Inventors: Tinnakorn Chaiworapongsa, Sonia S. Hassan, Roberto Romero